New methods of financing significant risk transfer investments are gaining momentum as investors tap into insurance demand for exposure to the asset class.
Credit insurers are a growing part of the SRT market, having made inroads by persuading some issuers (and regulators) to accept unfunded protection, but also by teaming up with others to do funded deals through repack structures.
Now, some insurers are matching their appetite for risk with specialist credit funds’ desire for leverage in inventive new structures, some of which are expected to close before year end.
Firms with insurance structuring and underwriting expertise like Karson Management, Ryan Specialty and Lockton Re have been pitching the novel structures to insurers and funders, in hopes of scaling them up as financing channels for SRT and other kinds of private credit.
The deals being worked on bring in insurers to cover the mezzanine tranche risk on pools of multiple SRT or private credit investments. The structures are also being set up in advance to fund and lever future investments.
The goal is to distribute the risk between specialist credit funds and insurers, while also financing the insurers’ portion, in a repeatable structure with low upfront and running costs.
However, obstacles remain – it is unclear whether these programmes will be able to reach the scale needed to offset financing and structuring costs, and structures must carefully address regulatory and accounting risks.
Insurance recap
Insurers can participate in SRTs from the liability side of their balance sheet, as an insurance policy, or the asset side of their balance sheet, as an investment.
Many insurers prefer the liability-side route over holding the asset because SRT is a largely illiquid, fairly short-dated credit, and subject to pre-payment. The typical insurance SRT deal is therefore an unfunded insurance contract which pays out against credit losses.
However, unfunded SRTs are currently less capital efficient in the EU, not permitted in the US and only recently got the green light in the UK.
To address those limitations, structures that allow insurers to participate with a funding component have gained popularity. Among them is the funded repack, in which an SPV purchases the SRT and an insurer takes the risk, but another institution provides funding.
It is harder for insurance companies to invest capital from the asset side of their balance sheets, since they have strong regulatory incentives to buy IG assets. Not only that, but securitisation positions carry heavy capital requirements under Europe’s Solvency II regime. As a result, EU insurers rarely invest in securitisations, including SRTs, compared to their US counterparts.
In the US, regulation means that banks have to offload thicker tranches risk to get capital relief on loan portfolios. To obtain their desired returns, some US investors seek to retranche their exposures and obtain ratings on the upper parts of the tranche, allowing them to place notes with investors including US insurers, as a form of structural leverage.
Bring on the insurers
The latest wave of innovation comes at an interesting time for investors that like to add leverage to their SRT positions to increase returns, especially on thicker, lower-yielding tranches.
Over the past year, regulators and in some cases even issuing banks have clamped down on the use of repo and other forms of bank leverage to finance SRT investments.
At the same time, insurers who understand and like the credit risk, but do not have balance sheet to deploy, have been seeking ways to increase their exposure to private and structured credit.
The structures proposed by firms like Karson, Ryan Specialty and Lockton Re, which go beyond the single-transaction structures like funded repacks, could be one answer to matching insurance risk appetite to funds’ desire for leverage.
Repacks are expensive. The spread on each individual transaction must be enough to reward the investor, the structurer, the insurer and the financing party.
Historically, banks like Commerzbank, BNP Paribas, MUFG and NatWest have been involved in providing financing solutions to insurance-guaranteed products, but pricing remains expensive.
The newly proposed multi-investment structure, if it can be scaled and commoditised, should be cheaper, according to sources. Pension funds or asset-side insurers interested in IG-exposure could theoretically also finance these structures, in addition to banks.
The main structure gaining momentum looks something like this:
- A credit investor transfers multiple SRT and/or private credit investments from their portfolio into a vehicle.
- The mezzanine risk portion of those investments is wrapped by an insurer.
- The insured portion is financed at a high loan-to-value, either by a bank or another investor, which is exposed to the insurer’s default risk and rating.
This set-up provides financing for a vehicle containing existing SRT exposures, but another version of this structure can also provide insured financing for future investments.
The risk absorbed by the insurers and funded by other third parties would work to support investment activities like fundraising and forms of leveraged financing.
The structure is likely to appeal to property and casualty insurers looking to add risk on the liability side of their balance sheet.
The handful of deals in the works involve predominantly US firms, though UK and European investors have also explored these structures. Many of the investors will also have a Cayman Islands entity through which they can do business.
Wrap artists
Karson Management has operated as a principal in financing transactions since 2009. The firm aims to provide a financing ecosystem built around a special purpose company complex in Bermuda and its Delaware-domiciled KCL Master Trust, where the smaller companies within the larger complex can transact and lend to funds.
Karson is aiming to create a commoditised platform for these sorts of structures, broadening access for insurers and financing providers. It is working on its first transaction with a credit fund to bring in reinsurance risk capital for future fund investments.
Ryan Specialty is a wholesale broker and managing underwriter, founded in 2010. It offers structured credit insurance and non-payment insurance.
The firm has been pitching a structure that would provide up to an 80% advance rate on an SPV that contains multiple SRT notes. In its structure, the credit investor puts multiple SRTs from its portfolio into a vehicle and works with insurance firms to insure a portion of the cash flows.
Ryan Specialty has a partnership with Nationwide Mutual Insurance Company, an Ohio-based group, which has taken the risk on in certain transactions. Ryan Specialty and Nationwide announced a joint venture to create a new reinsurance company, Geneva Re, in 2019.
Lockton Re is a broker working with firms like Karson and Ryan Specialty to find reinsurers for these structures. It is the global reinsurance arm of Lockton, a privately-owned insurance brokerage firm founded in 1966.
One of Lockton Re’s transactions of this kind centres on funding SRT investments, while two others involve mixed pools of private credit assets, 9fin understands.
Lockton Re has also worked with insurers on structures involving rated notes.
Consolidation risk
Exactly what the insurer is wrapping has implications. Part of the difficulty involved in structuring these deals is handling consolidation risk.
Consolidating a transaction means booking all its components in one’s own accounts, and there is a huge difference between an insurer booking insurance to an SPV versus what is inside the SPV.
While the insurers may aim to book the insurance policy as a liability to the SPV, there is a risk that some of the underlying exposures end up on the asset side of its balance sheet, which comes with a much higher regulatory capital charge.
An insurance company must consolidate a transaction or entity if it has “control” under the relevant accounting framework, which includes factors like bearing the majority of the risk and returns, controlling underwriting decisions or directing investment strategy.
If a transaction is structured in a way where the insurer must consolidate the SPV into its accounts, it has to bring all the SPV’s assets and liabilities onto its balance sheet.
This means that the underlying mezzanine risk/interest in the fund could end up being booked on the asset side of the insurer’s balance sheet and the financing component as a debt on the liability side.
Consolidation treatment is highly dependent upon the facts of each individual transaction and will likely have to be cleared by each firm’s accounting advisors.
Ideally for the insurer, the transaction will be structured so that the SRT fund manager is the one who consolidates the SPV. On paper, a general partner will control the SPV.
The fund will have to explain the arrangement to its end investors, or limited partners, and address whether LPs in the fund are pari passu with the insurers and the funding provider.
Whether the transaction is structured as a funded SPV with an embedded insurance policy or as a loan to an SPV which is then insured also has capitalisation implications for a funding bank. The distinction is subtle, but the former is more capital efficient for both the bank and insurer.
Insurers as investors
In some ways, the emerging technique is similar to another strategy which has also been employed recently, but which involves insurance companies as investors, deploying capital from the asset side of their balance sheets, rather than as insurance providers taking on liabilities.
As with the structure described above, this technique begins with an investor putting multiple SRT notes into a vehicle. But this time, rather than being covered by an insurance policy, the mezzanine portion is rated by a credit rating agency.
The rated portion is then privately placed with investors looking for rated debt — life insurers are a classic example.
The diversification of the underlying SRT investments in the SPV helps improve the efficiency of the deal, lowering the investment-grade attachment point, according to sources.
“If you put five to six deals together, you can [lower the IG attachment point and] engineer 35-45% IG,” said a market participant. “You’re just financing an SPV.”
For these deals, a structurer helps set up the vehicle and sell the rated notes and profits through a gain on the sale of the notes.
Deutsche Bank has acted as a structurer in such transactions in the past and KBRA has privately rated some of the structures. Deutsche and KBRA declined to comment.
The newer structures being explored by the likes of Karson aim to achieve a similar result but at a lower cost, primarily by cutting out the rating agency fees.
The provider of the insurance contract acts almost as the equivalent of a rating agency. It evaluates the risk of the underlying SRTs, but rather than assigning a credit rating, it charges an insurance premium to cover losses. When it comes to financing the insured tranche, it effectively bears the IG rating of the insurer.
“That cheapens the funding so much,” said the market participant.
“The insurance company can capture the difference between what a triple B-rated note versus what a single-A or double-A guaranteed note would trade for, and that’s probably between 150bps to 200bps.”
Resecuritisation risk
Depending on the final structures, these new proposals risk falling under the definition of resecuritisation in the EU or UK, where resecuritisation is banned.
In simple terms, a resecuritisation is a securitisation whose underlying exposures are themselves securitisation positions.
To meet the definition of a securitisation for the purposes of EU and UK regulations, a transaction must involve the tranching of credit risk associated with a pool of exposures and payments must depend on the performance of the exposures.
Proponents of the insurance-based structures argue that they are not resecuritisations, and therefore comply with these regulations, in part because there is no re-tranching of the underlying exposures. One market participant described it as “secured financing for the SPV”.
The involved parties on the insurance and investor side have tended to act out of US, Bermuda and Cayman Islands entities, in part due to these resecuritisation concerns, although EU and UK entities have taken an interest and found legal opinions to support these structures as compliant.






